Journal
PLACENTA
Volume 109, Issue -, Pages -Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/j.placenta.2021.04.007
Keywords
Preeclampsia; Nicotinamide; sFlt-1; Soluble endoglin; Placenta
Funding
- NHMRC Early Career Fellowship [1142636]
- Norman Beischer Medical Research Foundation
- NHMRC [1136418, 1146128]
- National Health and Medical Research Council of Australia [1146128, 1136418] Funding Source: NHMRC
Ask authors/readers for more resources
The study found that nicotinamide (vitamin B3) did not show an effect on reducing markers of preeclampsia in primary human placental tissues and vascular cells.
Preeclampsia is a serious pregnancy complication associated with elevated antiangiogenic markers and endothelial dysfunction. Recently nicotinamide (vitamin B3) was shown to reduce high blood pressure and proteinuria in mice models of the disease. Using primary human pregnancy tissue we show nicotinamide did not change antiangiogenic factor secretion including soluble fms-like tyrosine kinase 1 or soluble endoglin from primary cytotrophoblasts and placental explants. Furthermore, it did not reverse markers of endothelial dysfunction. Therefore, we did not demonstrate an effect of nicotinamide on reducing markers of preeclampsia from primary human placental tissues and vascular cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available